Our Patients
1 in 10 individuals is affected by autoimmune disease
The increasing prevalence of autoimmune diseases has become one of the leading concerns in public health. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues in the body, leading to chronic inflammation, tissue damage, and organ dysfunction. As more people are diagnosed with autoimmune disease, the burden on healthcare systems, families, and communities grows.
Resetting the body’s response for individuals with autoimmune disorders
At Artax Biopharma, we are working on a novel approach to address many autoimmune diseases. Autoimmune diseases arise when the body loses its ability to distinguish between pathogenic antigens and self, thereby attacking the body’s cells as if they were pathogens. With our first-in-class drug candidates, we aim to modulate, or reset, the body’s immune response so that recognition of self is more normal again, while maintaining the ability to fight true pathogens.
We aim for a universal therapy with broad application in autoimmune diseases
We are searching for a universal therapy to treat autoimmune disease: a pill to address a wide range of autoimmune diseases, without causing the immune suppression that drives so many unwanted side effects, while still preserving the body’s normal immune responses. We have seen strong preclinical evidence of activity in the Th2, Th17, Th1/Th0 pathways, suggesting potential use across the autoimmune space.
About our clinical trials
- Phase 2a clinical trial of AX-158 in psoriasis patients
Phase 2a clinical trial of AX-158 in psoriasis patients
We completed recruitment for a Phase 2 trial with AX-158 in psoriasis patients in the UK. Learn more here.